EMA unveils 'new approach' to drugs for MDR bacteria
This article was originally published in SRA
Executive Summary
The European Medicines Agency has published additional guidance on the development of new antibacterial drugs, including what it calls a "new approach" to agents targeting multidrug-resistant pathogens with few or no treatment options, where limited clinical data may be accepted for approval purposes1,2.